Clinical trials: Mecamylamine
Major Depressive Disorder, Depression
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken together with another antidepressant.
- Trial name
- NCT01153347
- Testing
- TC-5214
- Where
- 99 sites in United States, India and 1 more
- Volunteers
- 2,409 people
- Sponsor
- AstraZeneca
Alcoholism
Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients
The purpose of the study will be to evaluate the efficacy of mecamylamine in reducing alcohol consumption in smoking and non-smoking alcohol dependent patients.
- Trial name
- NCT00342563
- Testing
- mecamylamine
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Yale University
Major Depressive Disorder
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like a medicine tablet or capsule, but contains no active medicine) is safe and effective when taken together with another antidepressant.
- Trial name
- NCT01197508
- Testing
- TC-5214
- Where
- 87 sites in Argentina, Brazil and 15 more
- Volunteers
- 696 people
- Sponsor
- AstraZeneca
Major Depressive Disorder, MDD
A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken for 52 weeks with another antidepressant…
- Conditions
- Major Depressive Disorder, MDD, Depression
- Trial name
- NCT01152554
- Testing
- TC-5214
- Where
- 94 sites in United States, Puerto Rico
- Volunteers
- 813 people
- Sponsor
- AstraZeneca
Major Depressive Disorder, Depression
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken together with another antidepressant.
- Trial name
- NCT01180400
- Testing
- TC-5214
- Where
- 66 sites in Czechia, Estonia and 8 more
- Volunteers
- 295 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.
The purpose of this study is to assess the safety and effect of TC-5214 as a single therapy in patients with major depressive disorder who exhibit inadequate response to antidepressants.
- Trial name
- NCT01288079
- Testing
- TC-5214, Duloxetine
- Where
- 63 sites in United States, Estonia and 3 more
- Volunteers
- 145 people
- Sponsor
- AstraZeneca
Major Depressive Disorder, Depression
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken together with another antidepressant.
- Trial name
- NCT01157078
- Testing
- TC-5214
- Where
- 51 sites in United States, India
- Volunteers
- 319 people
- Sponsor
- AstraZeneca
Alcohol Dependence, Depression
Mecamylamine for the Treatment of Patients With Depression and Alcohol Dependence
The objective of this study is to evaluate the efficacy of mecamylamine (MEC, 10 mg/day) versus placebo in reducing depressive and alcohol symptoms in patients with depression and co-morbid alcohol dependence.
- Trial name
- NCT00563797
- Testing
- Mecamylamine
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Yale University
Magnetic Resonance Imaging, Cognition
Nicotinic Modulation of the Default Network
Many disorders where attentional problems are a hallmark, such as Alzheimer's disease and schizophrenia, display abnormal regulation of the so-called default network of resting brain function that maintains internally directed…
- Conditions
- Magnetic Resonance Imaging, Cognition, Nicotine, Mecamylamine
- Trial name
- NCT01223404
- Testing
- Nicotine, Mecamylamine
- Where
- 2 sites in United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Cognition in Schizophrenia
Study of the Effects of Mecamylamine and Varenicline in Schizophrenia
We are conducting this study to find out if blocking or partially stimulating the effects of nicotine in the brain can affect memory and concentration. Nicotine is the addictive drug found in tobacco products.
- Trial name
- NCT00455650
- Testing
- Mecamylamine, Varenicline
- Where
- United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital